Market capitalization | $3.32b |
Enterprise Value | $2.56b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.27 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-271.08m |
Free Cash Flow (TTM) Free Cash Flow | $-220.31m |
Cash position | $778.84m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a Dyne Therapeutics Inc forecast:
10 Analysts have issued a Dyne Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.95 -1.95 |
16%
16%
|
|
EBITDA | -269 -269 |
40%
40%
|
EBIT (Operating Income) EBIT | -271 -271 |
39%
39%
|
Net Profit | -258 -258 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Head office | United States |
CEO | John Cox |
Employees | 141 |
Founded | 2017 |
Website | www.dyne-tx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.